According to life-table analysis , the proportion of patients in remission after 12 and 24 months was 96 4 and 86 7 % in patients receiving AZA versus 76 8 and 68 9 % in patients receiving placebo ( month 12 , p = 0.035 ; month 24 , p = 0.30 ) .